Lerdelimumab Biosimilar – Anti-TGFB2 mAb – Research Grade

Description of Lerdelimumab Biosimilar - Anti-TGFB2 mAb - Research Grade

Introduction

Lerdelimumab Biosimilar, also known as Anti-TGFB2 mAb, is a monoclonal antibody that targets the transforming growth factor beta 2 (TGFB2) protein. It is a research grade antibody that has shown promising results in pre-clinical studies and is currently being evaluated for its therapeutic potential in various diseases.

Structure

Lerdelimumab Biosimilar is a recombinant humanized antibody, meaning it is produced in a laboratory using genetic engineering techniques. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains are approximately 50 kDa in size and the light chains are approximately 25 kDa. The antibody has a molecular weight of around 150 kDa.

Activity

Lerdelimumab Biosimilar specifically targets and binds to the TGFB2 protein, a member of the transforming growth factor beta family. TGFB2 is a cytokine that plays a crucial role in cell growth, differentiation, and immune response. It is known to be involved in various diseases such as fibrosis, cancer, and autoimmune disorders.

By binding to TGFB2, Lerdelimumab Biosimilar inhibits its activity and prevents it from binding to its receptors on the cell surface. This leads to a decrease in the production of pro-inflammatory cytokines and an increase in anti-inflammatory cytokines, resulting in an overall anti-inflammatory effect. Additionally, Lerdelimumab Biosimilar also blocks the activation of fibroblasts, which are responsible for the deposition of scar tissue in fibrotic diseases.

Application

Lerdelimumab Biosimilar has shown potential as a therapeutic agent in various diseases. It is currently being evaluated in pre-clinical studies for its efficacy and safety in the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis, liver fibrosis, and systemic sclerosis.

In idiopathic pulmonary fibrosis, Lerdelimumab Biosimilar has been shown to reduce the expression of TGFB2 and other pro-fibrotic cytokines in lung tissue, leading to a decrease in fibrosis and improvement in lung function. In liver fibrosis, it has been found to reduce the deposition of scar tissue and improve liver function. In systemic sclerosis, Lerdelimumab Biosimilar has been shown to decrease skin thickness and improve symptoms in animal models.

Moreover, Lerdelimumab Biosimilar has also shown potential in the treatment of cancer. TGFB2 is known to play a role in tumor progression and metastasis, and by blocking its activity, Lerdelimumab Biosimilar may help in inhibiting tumor growth and spread. It is currently being studied in various types of cancer, including breast, lung, and colon cancer.

Conclusion

Lerdelimumab Biosimilar, also known as Anti-TGFB2 mAb, is a research grade monoclonal antibody that specifically targets the TGFB2 protein. By inhibiting its activity, it has shown potential in the treatment of fibrotic diseases and cancer. Further studies are needed to fully understand its therapeutic potential and determine its safety and efficacy in clinical settings. However, Lerdelimumab Biosimilar holds promise as a potential treatment option for various diseases and may provide a new avenue for therapeutic intervention.